基于多学科管理的慢性肾脏病1~3期患者中医食疗“定性+定量”双重干预方案的构建及实证研究

注册号:

Registration number:

ITMCTR2100005401

最近更新日期:

Date of Last Refreshed on:

2021-04-25

注册时间:

Date of Registration:

2021-04-25

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于多学科管理的慢性肾脏病1~3期患者中医食疗“定性+定量”双重干预方案的构建及实证研究

Public title:

Construction and Empirical Study of Dietary Therapy of TCM with “Qualitative+Quantitative” Dual Intervention for Chronic Kidney Disease Stage 1-3 Patients Based on Multidisciplinary Management

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于多学科管理的慢性肾脏病1~3期患者中医食疗“定性+定量”双重干预方案的构建及实证研究

Scientific title:

Construction and Empirical Study of Dietary Therapy of TCM with “Qualitative+Quantitative” Dual Intervention for Chronic Kidney Disease Stage 1-3 Patients Based on Multidisciplinary Management

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100045883 ; ChiMCTR2100005401

申请注册联系人:

张帆

研究负责人:

张帆

Applicant:

Zhang Fan

Study leader:

Zhang Fan

申请注册联系人电话:

Applicant telephone:

+86 18817771780

研究负责人电话:

Study leader's telephone:

+86 18817771780

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1051071914@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1051071914@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海徐汇区宛平南路725号

研究负责人通讯地址:

上海徐汇区宛平南路725号

Applicant address:

725 Wanping Road South, Xuhui District, Shanghai

Study leader's address:

725 Wanping Road South, Xuhui District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学附属龙华医院

Applicant's institution:

Longhua Hospital Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2021-092

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海中医药大学附属龙华医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Longhua Hospital Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2021/7/29 0:00:00

伦理委员会联系人:

刘胜

Contact Name of the ethic committee:

Liu Sheng

伦理委员会联系地址:

上海徐汇区宛平南路725号

Contact Address of the ethic committee:

725 Wanping Road South, Xuhui District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属龙华医院

Primary sponsor:

Longhua Hospital Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海徐汇区宛平南路725号

Primary sponsor's address:

725 Wanping Road South, Xuhui District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

具体地址:

徐汇区宛平南路725号

Institution
hospital:

Longhua Hospital Shanghai University of Traditional Chinese Medicine

Address:

725 Wanping Road South, Xuhui District

经费或物资来源:

上海护理学会

Source(s) of funding:

Shanghai Nursing Association

研究疾病:

慢性肾脏病

研究疾病代码:

Target disease:

Chronic Kidney Disease

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.建立中医症型为肝肾阴虚、肺肾气虚、脾肾阳虚、气阴两虚的CKD患者的饮食处方库。 2.构建CKD 1~3期患者的中医食疗“定性+定量”双重干预方案并评估其效果。

Objectives of Study:

1. To establish the diet prescription database of chronic disease patients with TCM syndrome types of liver and yin deficiency, lung and qi deficiency, spleen and yang deficiency, Qi and yin deficiency. 2. To construct dietary therapy of TCM with qualitative+quantitative dual intervention for chronic disease stage 1-3 patients and evaluate its effect.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.根据改善全球预后肾脏病组织(KDIGO)诊断为1~3期,且中医辨证为肝肾阴虚、肺肾气虚、脾肾阳虚、气阴两虚的CKD患者; 2.中年患者,即年龄为40~55岁; 3.患者为高中及以上学历,依从性良好,签署知情同意书,符合本院医学伦理委员会对医学伦理的要求。

Inclusion criteria

1. According to the Global Prognosis Improvement Kidney Disease Organization (KDIGO) , patients with CKD diagnosed as stage 1-3, and TCM syndromes are liver and kidney yin deficiency, lung and kidney qi deficiency, spleen and kidney yang deficiency, and qi and yin deficiency; 2. Middle-aged patients, aged 40 to 55 years; 3. The patient has a high school degree or above, has good compliance, and signed an informed consent, which meets the medical ethics requirements of the medical ethics committee of this hospital.

排除标准:

1.合并有心、脑血管及胃肠道疾病者; 2.根据营养风险筛查简表(NRS 2002)判断为中、重度营养不良者; 3.严重血液疾病、恶性肿瘤者; 4.合并有甲亢等严重影响营养代谢者。

Exclusion criteria:

1. Patients with heart, cerebrovascular and gastrointestinal diseases; 2. According to the Nutrition Risk Screening Summary (NRS 2002) judged as moderately or severely malnourished; 3. Severe blood diseases or malignant tumors; 4. Combined with hyperthyroidism and other severely affecting nutrition metabolism.

研究实施时间:

Study execute time:

From 2021-01-01

To      2022-12-31

征募观察对象时间:

Recruiting time:

From 2021-08-01

To      2022-10-31

干预措施:

Interventions:

组别:

肝肾阴虚组

样本量:

15

Group:

Liver and Kidney Yin Deficiency Group

Sample size:

干预措施:

饮食干预

干预措施代码:

Intervention:

Diet intervention

Intervention code:

组别:

肺肾气虚组

样本量:

15

Group:

Lung and Kidney Qi Deficiency Group

Sample size:

干预措施:

饮食干预

干预措施代码:

Intervention:

Diet intervention

Intervention code:

组别:

气阴两虚组

样本量:

15

Group:

Qi and Yin Deficiency Group

Sample size:

干预措施:

饮食干预

干预措施代码:

Intervention:

Diet intervention

Intervention code:

组别:

脾肾阳虚组

样本量:

15

Group:

Spleen and Kidney Yang Deficiency Group

Sample size:

干预措施:

饮食干预

干预措施代码:

Intervention:

Diet intervention

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属龙华医院

单位级别:

三级甲等

Institution/hospital:

Longhua Hospital Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肾功能

指标类型:

主要指标

Outcome:

Renal function

Type:

Primary indicator

测量时间点:

测量方法:

肾小球滤过率

Measure time point of outcome:

Measure method:

Estimated Glomerular Filtration Rate

指标中文名:

人体成分

指标类型:

次要指标

Outcome:

Body composition

Type:

Secondary indicator

测量时间点:

测量方法:

基于人体成分仪测量结果

Measure time point of outcome:

Measure method:

Based on the measurement results of body composition measurement

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

Quality of life

Type:

Secondary indicator

测量时间点:

测量方法:

健康调查简表

Measure time point of outcome:

Measure method:

SF-36

指标中文名:

营养状况

指标类型:

次要指标

Outcome:

Nutrition status

Type:

Secondary indicator

测量时间点:

测量方法:

基于血清白蛋白水平

Measure time point of outcome:

Measure method:

Based on serum albumin level

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 40
Min age years
最大 55
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not applicable

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023年06月 请阅读网页注册指南中关于 原始数据共享 的内容。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

June 2023

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management consists of two parts, one is case record form, and the other is the electronic data capture and management system.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统